Konference: 2009 34st Congress ESMO a 15th Congress ECCO - účast ČR
Kategorie: Genitourinární nádory
Téma: Poster Session III: Diagnostic/Biomarkers
Číslo abstraktu: P-1336
Autoři: doc. MUDr. Otakar Kopecký, CSc.; MUDr. Šárka Lukešová, Ph.D.; MUDr. Dagmar Hlávková, Ph.D.; Mgr. Vladimíra Vroblová, Ph.D.; Doc.RNDr. Ctirad Andrýs, Ph.D.; MUDr. Petr Morávek, CSc.; RNDr. Eva Čermáková, CSc.
Background: To determine the selected serum angiogenic
factors in patients with newly diagnosed renal tumor (RCC) and to
correlate them with the clinical stage of the disease.
Patients: Nephrectomy or partial kidney resection was performed in 54 patients (34 men, 20 women) with newly diagnosed renal cell carcinoma (RCC). The mean age of patients was 64.4 years. The patients were divided into three groups based on the TNM classification: the 1st group ¨C stages I + II, the 2nd group ¨C stage III, the 3rd group ¨C stage IV.
Method: The serum levels (collected before surgery) of GRO¦Á (CXCL1), IL-8 (CXCL8), IL-6, VEGF and bFGF were determined by the ELISA method. Clinical data (age, sex, tumor histopathology grading (HPG), disease progression and death during a-12-month follow-up period) were compared with serum levels of angiogenic factors. Kruskal-Wallis ANOVA, Mann-Whitney's test and Kolmogorov-Smirnov's test were used.
Results: In case of GRO¦Á, a significant difference was found between patients with and without progression period (p = 0.006), between surviving and dead patients (p = 0.038), between the1st and the 4th grade of HPG (p = 0.05), between the 2nd and the 4th grade of HPG (p = 0.0043) and between the 3rd and the 4th grade of HPG (p = 0.044). A statistically significant difference in serum concentration of IL-8 was found between patients with and without progression (p = 0.007), but no differences were found between the dead and surviving patients and between the various grades of HPG. A statistically significant differences in serum concentration of IL-6 were found between patients with and without progression (p = 0.0006) between dead and surviving patients (p = 0.0042), between the1st and the 4th grade of HPG (p = 0.05) and between the 2nd and the 4th grade of HPG (p = 0.0041). A statistically significant difference in serum levels of VEGF was found between patients with and without progression (p = 0.0026), between dead and surviving patients (p = 0.021). A statistically significant difference in serum levels of bFGF was found between dead and surviving patients (p = 0.024).
Conclusion: Out of the ten tested angiogenic factors, we found a correlation between serum levels and clinical findings for GRO¦Á, IL-8, IL-6, VEGF and bFGF. However, their use in clinical practice should be verified on a larger group of patients.
This study was supported by the grant from the Internal Grant Agency of the Czech Republic Ministry of Health: NR/8914¨C4.
Publikováno v: European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 149
Patients: Nephrectomy or partial kidney resection was performed in 54 patients (34 men, 20 women) with newly diagnosed renal cell carcinoma (RCC). The mean age of patients was 64.4 years. The patients were divided into three groups based on the TNM classification: the 1st group ¨C stages I + II, the 2nd group ¨C stage III, the 3rd group ¨C stage IV.
Method: The serum levels (collected before surgery) of GRO¦Á (CXCL1), IL-8 (CXCL8), IL-6, VEGF and bFGF were determined by the ELISA method. Clinical data (age, sex, tumor histopathology grading (HPG), disease progression and death during a-12-month follow-up period) were compared with serum levels of angiogenic factors. Kruskal-Wallis ANOVA, Mann-Whitney's test and Kolmogorov-Smirnov's test were used.
Results: In case of GRO¦Á, a significant difference was found between patients with and without progression period (p = 0.006), between surviving and dead patients (p = 0.038), between the1st and the 4th grade of HPG (p = 0.05), between the 2nd and the 4th grade of HPG (p = 0.0043) and between the 3rd and the 4th grade of HPG (p = 0.044). A statistically significant difference in serum concentration of IL-8 was found between patients with and without progression (p = 0.007), but no differences were found between the dead and surviving patients and between the various grades of HPG. A statistically significant differences in serum concentration of IL-6 were found between patients with and without progression (p = 0.0006) between dead and surviving patients (p = 0.0042), between the1st and the 4th grade of HPG (p = 0.05) and between the 2nd and the 4th grade of HPG (p = 0.0041). A statistically significant difference in serum levels of VEGF was found between patients with and without progression (p = 0.0026), between dead and surviving patients (p = 0.021). A statistically significant difference in serum levels of bFGF was found between dead and surviving patients (p = 0.024).
Conclusion: Out of the ten tested angiogenic factors, we found a correlation between serum levels and clinical findings for GRO¦Á, IL-8, IL-6, VEGF and bFGF. However, their use in clinical practice should be verified on a larger group of patients.
This study was supported by the grant from the Internal Grant Agency of the Czech Republic Ministry of Health: NR/8914¨C4.
Publikováno v: European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 149
Datum přednesení příspěvku: 22. 9. 2009
